Belgian RSV vaccine rollout cuts infant hospitalizations by 3,500

New research in Belgium shows nirsevimab, an RSV vaccine for infants, prevented approximately 3,500 hospital admissions in its first year of use. The finding confirms real-world effectiveness of the immunization program as the next RSV season approaches, with pediatricians urging vaccination for infants under six months.